• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应用于BioFIND队列中已确诊帕金森病的新诊断和分期框架。

New diagnostic and staging framework applied to established PD in the BioFIND cohort.

作者信息

Russo Marco J, Kang Un Jung

机构信息

Movement Disorders Division, Department of Neurology, Rutgers University, Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

The Marlene and Paolo Fresco Institute for Parkinson's & Movement Disorders, Department of Neurology, Department of Neuroscience and Physiology, Neuroscience Institute, The Parekh Center for Interdisciplinary Neurology, NYU Grossman School of Medicine, New York, NY, USA.

出版信息

NPJ Parkinsons Dis. 2025 Jun 4;11(1):151. doi: 10.1038/s41531-025-00992-3.

DOI:10.1038/s41531-025-00992-3
PMID:40467579
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12137746/
Abstract

The proposed Neuronal α-Synuclein Disease Integrated Staging System (NSD-ISS) was recently applied to early Parkinson's disease (PD) cohorts. We applied this research framework to the BioFIND study cohort, which includes more moderately advanced PD participants with clinically established PD. Disease durations within each ISS stage were highly variable. Cognitive and non-motor anchors had little weight in determining staging. The analysis highlights strengths and limitations of NSD-ISS to guide further refinement of an integrated staging system.

摘要

最近,所提出的神经元α-突触核蛋白病综合分期系统(NSD-ISS)被应用于早期帕金森病(PD)队列。我们将这个研究框架应用于BioFIND研究队列,该队列包括更多临床确诊的中度进展期PD参与者。每个ISS阶段内的病程差异很大。认知和非运动指标在确定分期时权重较小。该分析突出了NSD-ISS的优势和局限性,以指导综合分期系统的进一步完善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde7/12137746/22a782f70415/41531_2025_992_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde7/12137746/22a782f70415/41531_2025_992_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dde7/12137746/22a782f70415/41531_2025_992_Fig1_HTML.jpg

相似文献

1
New diagnostic and staging framework applied to established PD in the BioFIND cohort.应用于BioFIND队列中已确诊帕金森病的新诊断和分期框架。
NPJ Parkinsons Dis. 2025 Jun 4;11(1):151. doi: 10.1038/s41531-025-00992-3.
2
New Diagnostic and Staging Framework Applied to Established PD in the BioFIND Cohort.应用于BioFIND队列中已确诊帕金森病的新诊断和分期框架。
Res Sq. 2025 Apr 28:rs.3.rs-6003205. doi: 10.21203/rs.3.rs-6003205/v1.
3
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts.神经元α-突触核蛋白病综合分期系统在PPMI、帕萨迪纳和SPARK基线队列中的表现。
medRxiv. 2024 Sep 10:2024.02.14.24302818. doi: 10.1101/2024.02.14.24302818.
4
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts.神经元α-突触核蛋白病综合分期系统在PPMI、帕萨迪纳和SPARK基线队列中的表现。
NPJ Parkinsons Dis. 2024 Sep 27;10(1):178. doi: 10.1038/s41531-024-00789-w.
5
SynNeurGe: The road ahead for a biological definition of Parkinson's disease.SynNeurGe:帕金森病生物学定义的未来之路。
J Parkinsons Dis. 2024 Dec 8:1877718X241298194. doi: 10.1177/1877718X241298194.
6
Neuronal α-Synuclein Disease Stage Progression over 5 Years.神经元α-突触核蛋白疾病5年的阶段进展
Mov Disord. 2025 Apr 30. doi: 10.1002/mds.30191.
7
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.神经元α-突触核蛋白病的生物学定义:建立研究用综合分期系统。
Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2.
8
Eleven Years of Change: Disease Progression in Biomarker-Defined Sporadic Parkinson's Disease.十一年的变化:生物标志物定义的散发性帕金森病的疾病进展
medRxiv. 2024 Oct 10:2024.10.09.24315191. doi: 10.1101/2024.10.09.24315191.
9
Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.生物标志物研究中的脑脊液、血浆和唾液:生物标志物与帕金森病特征的关系。
Mov Disord. 2018 Feb;33(2):282-288. doi: 10.1002/mds.27232. Epub 2017 Dec 4.
10
Elevated ApoE, ApoJ and lipoprotein-bound α-synuclein levels in cerebrospinal fluid from Parkinson's disease patients - Validation in the BioFIND cohort.帕金森病患者脑脊液中载脂蛋白 E、载脂蛋白 J 和脂蛋白结合的α-突触核蛋白水平升高 - 在 BioFIND 队列中的验证。
Parkinsonism Relat Disord. 2023 Nov;116:105765. doi: 10.1016/j.parkreldis.2023.105765. Epub 2023 Jul 12.

本文引用的文献

1
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts.神经元α-突触核蛋白病综合分期系统在PPMI、帕萨迪纳和SPARK基线队列中的表现。
NPJ Parkinsons Dis. 2024 Sep 27;10(1):178. doi: 10.1038/s41531-024-00789-w.
2
Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.持续皮下左旋多巴-卡比多巴输注(ND0612)治疗帕金森病伴运动波动(BouNDless)的安全性和有效性:一项 3 期、随机、双盲、双模拟、多中心试验。
Lancet Neurol. 2024 May;23(5):465-476. doi: 10.1016/S1474-4422(24)00052-8. Epub 2024 Mar 15.
3
A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria.
帕金森病的生物学分类:SynNeurGe 研究诊断标准。
Lancet Neurol. 2024 Feb;23(2):191-204. doi: 10.1016/S1474-4422(23)00404-0.
4
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.神经元α-突触核蛋白病的生物学定义:建立研究用综合分期系统。
Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2.
5
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial.IPX203与速释卡比多巴-左旋多巴治疗帕金森病运动波动的疗效比较:RISE-PD随机临床试验
JAMA Neurol. 2023 Oct 1;80(10):1062-1069. doi: 10.1001/jamaneurol.2023.2679.
6
Dysautonomia and REM sleep behavior disorder contributions to progression of Parkinson's disease phenotypes.自主神经功能障碍和快速眼动睡眠行为障碍对帕金森病表型进展的影响。
NPJ Parkinsons Dis. 2022 Aug 30;8(1):110. doi: 10.1038/s41531-022-00373-0.
7
Motor phenotype classification in moderate to advanced PD in BioFIND study.BioFIND 研究中中重度至晚期 PD 的运动表型分类。
Parkinsonism Relat Disord. 2019 Aug;65:178-183. doi: 10.1016/j.parkreldis.2019.06.017. Epub 2019 Jun 23.
8
Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson's disease.对比研究脑脊液α-突触核蛋白种子聚合分析在帕金森病诊断中的应用。
Mov Disord. 2019 Apr;34(4):536-544. doi: 10.1002/mds.27646. Epub 2019 Mar 6.
9
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.生物标志物发现(BioFIND)研究:临床典型帕金森病生物标志物队列的特征
Mov Disord. 2016 Jun;31(6):924-32. doi: 10.1002/mds.26613. Epub 2016 Apr 26.
10
Course in Parkinson disease subtypes: A 39-year clinicopathologic study.帕金森病亚型病程:一项39年的临床病理研究。
Neurology. 2009 Jul 21;73(3):206-12. doi: 10.1212/WNL.0b013e3181ae7af1.